Oyster Point raises $93M series B to bring dry eye nasal spray to FDA
By Elizabeth S. Eaton | Feb 26, 2019 | 2:01 PM GMT
Editor's Note: This article was updated on Feb 27, 2019 at 2:26 AM GMT
Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million Tuesday in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA submission.
Read the full 368 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD